53 related articles for article (PubMed ID: 3043350)
21. [Pharmacokinetics of ponsinomycin administered in a syrup form in single 400-800 and 1200 mg doses in healthy volunteers].
Couet W; Girault J; Reigner B; Ingrand I; Bizouard J; Fourtillan JB
Pathol Biol (Paris); 1989 May; 37(5):428-32. PubMed ID: 2789363
[TBL] [Abstract][Full Text] [Related]
22. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data.
Yu LX; Amidon GL
Eur J Pharm Biopharm; 1998 Mar; 45(2):199-203. PubMed ID: 9704917
[TBL] [Abstract][Full Text] [Related]
23. Theoretical model for both saturable rate and extent of absorption: simulations of cefatrizine data.
Couet WR; Reigner BG; Guedes JP; Tozer TN
J Pharmacokinet Biopharm; 1991 Jun; 19(3):271-85. PubMed ID: 1875282
[TBL] [Abstract][Full Text] [Related]
24. Kinetics of cefatrizine penetration into gynaecological tissues after oral administration.
Fraschini F; Scaglione F; Proto M; Braga PC; Ciampini M
Chemotherapy; 1987; 33(2):93-6. PubMed ID: 3568802
[TBL] [Abstract][Full Text] [Related]
25. [Influence of food intake on the bioavailability of ponsinomycin administered in a syrup form].
Fourtillan JB; Couet W; Ingrand I; Reigner B; Bizouard J; Girault J
Pathol Biol (Paris); 1989 May; 37(5):446-50. PubMed ID: 2789364
[TBL] [Abstract][Full Text] [Related]
26. Cefatrizine (SK&F 60771), a new oral cephalosporin: serum levels and urinary recovery in humans after oral or intramuscular administration--comparative study with cephalexin and cefazolin.
Actor P; Pitkin DH; Lucyszyn G; Weisbach JA; Bran JL
Antimicrob Agents Chemother; 1976 May; 9(5):800-3. PubMed ID: 949177
[TBL] [Abstract][Full Text] [Related]
27. Determination of cefatrizine in serum and urine by reversed-phase high-performance liquid chromatography.
Crombez E; Van der Weken G; Van den Bossche W; De Moerloose P
J Chromatogr; 1979 May; 173(1):165-73. PubMed ID: 546870
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetics of BMY-28100 in multiple administration].
Motohiro T; Kawakami A; Sasaki H; Aramaki M; Sakata Y; Tominaga K; Yamashita F; Nakanomyo H; Hiraoka M; Ishikawa K
Jpn J Antibiot; 1990 Nov; 43(11):1893-7. PubMed ID: 2287056
[TBL] [Abstract][Full Text] [Related]
29. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects.
Meyer BH; Muller FO; Luus HG; Drees B; Röthig HJ; Badian M; Eckert HG
J Antimicrob Chemother; 1992 Apr; 29 Suppl A():63-70. PubMed ID: 1601759
[TBL] [Abstract][Full Text] [Related]
30. A double-blind clinical comparison of two dosage schedules of cefatrizine in children.
Careddu P; Ceccarelli G
J Int Med Res; 1988; 16(3):197-200. PubMed ID: 3044871
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of cefprozil in infants and children.
Sáez-Llorens X; Shyu WC; Shelton S; Kumiesz H; Nelson J
Antimicrob Agents Chemother; 1990 Nov; 34(11):2152-5. PubMed ID: 2073105
[TBL] [Abstract][Full Text] [Related]
32. [Experimental and clinical studies of cefatrizine in oral infections (author's transl)].
Ueda K; Tsuto H; Yamamoto T; Minami Y; Muraoka M; Tsushima T; Morihana T; Nagata K; Nakao K; Shimada K
Jpn J Antibiot; 1981 Jul; 34(7):1092-7. PubMed ID: 7321188
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and tissue penetration of ceftibuten.
Wise R; Nye K; O'Neill P; Wostenholme M; Andrews JM
Antimicrob Agents Chemother; 1990 Jun; 34(6):1053-5. PubMed ID: 2393265
[TBL] [Abstract][Full Text] [Related]
34. Comparative absorption following the administration of a drug to rats by oral gavage and incorporation in the diet.
Van Harken DR; Hottendorf GH
Toxicol Appl Pharmacol; 1978 Feb; 43(2):407-10. PubMed ID: 635927
[No Abstract] [Full Text] [Related]
35. Physicochemical properties of amphoteric beta-lactam antibiotics. IV. First- and second-order degradations of cefaclor and cefatrizine in aqueous solution and kinetic interpretation of the intestinal absorption and degradation of the concentrated antibiotics.
Nakashima E; Tsuji A; Nakamura M; Yamana T
Chem Pharm Bull (Tokyo); 1985 May; 33(5):2098-106. PubMed ID: 4053234
[No Abstract] [Full Text] [Related]
36. [Clinical results of cefatrizine in the field of oral surgery].
Takeda G; Kanamura S; Uematsu N; Saito H; Tojo H
Shikai Tenbo; 1985 Aug; 66(2):439-53. PubMed ID: 3909463
[No Abstract] [Full Text] [Related]
37. [Bricef (cefatrizine) for various infections in the orodental region].
Shiraishi T
Shikai Tenbo; 1984 Mar; 63(3):615-9. PubMed ID: 6591481
[No Abstract] [Full Text] [Related]
38. Predicting the time needed to achieve steady state if absorption and elimination constants are equal.
Singer J; Vereczkey L
J Pharmacokinet Biopharm; 1999 Jun; 27(3):297-300. PubMed ID: 10728491
[TBL] [Abstract][Full Text] [Related]
39. [Absorption and excretion of cefatrizine (S-640 P) in mouse and rat (author's transl)].
Matsuzaki M; Nakamura K; Hirata Y; Matsumoto H; Ochiai K
Jpn J Antibiot; 1976 Jan; 29(1):69-76. PubMed ID: 1263341
[No Abstract] [Full Text] [Related]
40. Saturable rate of cefatrizine absorption after oral administration to humans.
Reigner BG; Couet W; Guedes JP; Fourtillan JB; Tozer TN
J Pharmacokinet Biopharm; 1990 Feb; 18(1):17-34. PubMed ID: 2329468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
